drugset / Trial / NCT04907539
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
RandomizedSequentialOpen-labelTreatment
Summary
This is a Phase II, open label, multicentre, multi-arm, study to evaluate the preliminary efficacy and safety of RXC004 as monotherapy and in combination with nivolumab in patients with Ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, microsatellite stable (MSS), colorectal cancer (CRC), that have progressed following current standard of care treatment.
Timeline
- Start
- 2021-11-08
- Primary completion
- 2024-04-02
- Completion
- 2024-04-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | ZAMAPORVINT | Small molecule | 1.5 mg | Oral |
| Subject | ZAMAPORVINT | Small molecule | 2 mg | Oral |
| Background | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |